



#10 8/21/99
T. Gray
PATENT
Docket No: 2026-4124US3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Kawakami, et.al.

Group Art Unit: 1642

Serial No. : 09/073,138

Examiner: Johnson, N.

Filed : May 5, 1998

For : MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC
AND THERAPEUTIC METHODS

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

RECEIVED
TECH CENTER 1600/2900
99 AUG 18 AM 10:55

RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.111

Sir:

In response to the Official Action dated May 13, 1999, applicants present the following amendment and remarks.

IN THE CLAIMS

Please amend the claims as follows.

29. (amended) A pharmaceutical composition comprising gp100 (SEQ ID NO: 27) or an immunogenic peptide [having] consisting essentially of 5-20 contiguous amino acids within the gp100 sequence and a pharmacologically acceptable excipient, diluent or carrier.

30. (amended) A method of treating melanoma in a mammal comprising administering a pharmaceutical composition comprising gp100 (SEQ ID NO: 27) or an immunogenic peptide [having] consisting essentially of 5-20 contiguous amino acids within